Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-α promoter polymorphism

Digestion

Volumn 68, Issue 1, 2003, Pages 1-4

  Schiemann, Uwe ^a   Glas, J ^a   Torok P ^a   Simperl, C ^a   Martin, K ^a   Konig A ^a   Schmidt, F ^a   Schaefer, M ^b   Folwaczny, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic hepatitis C; Interferon alfa 2a; Ribavirin; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENE FREQUENCY; GENE LOCATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141924126     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073218     Document Type: Article

References (33)

1. National Institutes of Health: Management of hepatitis C. NIH Consensus Statement 1997;15:2-20.
2. Zavaglia C, Marinetti M, Silini E, et al: Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998;28:1-7.
3. Alric L, Izopet J, Fort M, et al: Study of the association between major histocompatibility complex class II genes and the response to interferon-α in patients with chronic hepatitis C infection. Hum Immunol 1999;60:516-523.
4. Vejbaesya S, Songsivilai S, Tanwandee T, et al: HLA association with hepatitis C virus infection. Hum Immunol 2000;61:348-353.
5. Woitas RP, Ahlenstiel G, Iwan A, et al: Frequency of the HIV-protective CC chemokine receptor 5 δ32/δ32 genotype is increased in hepatitis C. Gastroenterology 2002;122:1721-1728.
6. Nguyen GT, Carrington M, Beeler JA, et al: Phenotypic expressions of CCR5-δ32/δ32 homozygosity. J AIDS 1999;22:75-82.
7. Yee LJ, Jianming Tang J, et al: Interleukin-10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-712.
8. Larea E, Garcia N, Qian C, et al: Tumor necrosis factor-α gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23:210-217.
9. Nelson DR, Lim HL, Marousis CG, et al: Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Dig Dis Sci 1997;42:2487-2494.
10. Kallinowski B, Haseroth K, Marinos G, et al: Induction of tumor necrosis factor receptor type p55 and p75 in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1998;111:269-277.
11. Hohler T, Kruger A, Gerken G, et al: Tumor necrosis factor-α promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998;54:173-177.
12. Hohler T, Kruger A, Gerken G, et al: A tumor necrosis factor-α promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998;111:579-582.
13. Yee LJ, Tang J, Herrera J, et al: Tumor necrosis factor gene polymorphism in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
14. Dumoulin FL, Wennrich U, Nischalke HD, et al: Intrahepatic mRNA levels of interferon-γ and tumor necrosis factor-α and response to antiviral treatment of chronic hepatitis C. J Hum Virol 2001;4:195-199.
15. Taliani G, Badolato MC, Nigro G, et al: Serum concentration of γGT is a surrogate marker of hepatic TNF-α mRNA expression in chronic hepatitis C. Clin Immunol 2002;105:279-285.
16. Schaefer M, Schmidt F, Folwaczny C, et al: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451.
17. Mansfield JC, Holden H, Tarlow JK, et al: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.
18. Hajeer AH, Hutchinson IV: TNF-α gene polymorphism: Clinical and biological implications. Microsc Res Tech 2000;50:216-228.
19. Abraham LJ, Kroeger KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: Relevance to disease. J Leukoc Biol 1999;66:562-566.
20. McManus R, Wilson AG, Mansfield J, et al: TNF2, a polymorphism of the tumour necrosis-α gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 1996;2:2113-2118.
21. Bathgate AJ, Pravica V, Perrey C, et al: Polymorphisms in tumour necrosis factor-α, interleukin-10 and transforming growth factor-β1 genes and end-stage liver disease. Eur J Gastroenterol Hepatol 2000;12:1329-1333.
22. Michtell SA, Grove J, Spurkland A, et al: Association of the tumour necrosis factor-α -308 but not the interleukin-10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-294.
23. Roy S, McGuire W, Mascie-Taylor CG, et al: Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997;176:530-532.
24. Bikmaeva AR, Sibiriak SV, Valiakhmetova DKH, et al: Polymorphism of the tumor necrosis factor-α gene in patients with infiltrative tuberculosis and from the Bashkorstan populations (in Russian). Mol Biol (Mosk) 2002;36.784-787.
25. Freeman RB Jr, Tran CL, Mattoli J, et al: Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation. NEMC TNF Study Group. Transplantation 1999;67:1005-1010.
26. Fernandes H, Koneru B, Fernandes N, et al: Investigation of promoter polymorphisms in the tumor necrosis factor-α and interleukin-10 genes in liver transplant patients. Transplantation 2002;73:1886-1891.
27. Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998;91:3574-3581.
28. Demeter J, Messer G, Schrezenmeier H: Clinical relevance of the TNF-α promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol 2002;81:566-569.
29. Alvarez V, Mata IF, Gonzales P, et al: Association between the TNF-α-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 2002;114:574-577.
30. Yee LJ, Tang J, Gibson AW, et al: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-712.
31. Rosen HR, McHutchinson JG, Conrad AJ, et al: Tumor necrosis factor genetic polymorphism and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:714-720.
32. Tokushige K, Tsuchiya N, Hasegawa K, et al: Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV. Am J Gastroenterol 2003;98:160-166.
33. Vidigal PG, Germer JJ, Zein NN: Polymorphisms in the interleukin-10, tumor necrosis factor-α, and transforming growth factor-β1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002;36:271-277.